Cargando…
Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders
T cells are the current choice for many cell therapy applications. They are relatively easy to access, expand in culture, and genetically modify. Rapamycin‐conditioning ex vivo reprograms T cells, increasing their memory properties and capacity for survival, while reducing inflammatory potential and...
Autores principales: | Nagree, Murtaza S, Felizardo, Tania C, Faber, Mary L, Rybova, Jitka, Rupar, C Anthony, Foley, S Ronan, Fuller, Maria, Fowler, Daniel H, Medin, Jeffrey A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988206/ https://www.ncbi.nlm.nih.gov/pubmed/35298086 http://dx.doi.org/10.15252/emmm.202114297 |
Ejemplares similares
-
Host Interactions with Engineered T-cell Micropharmacies
por: Bourne, Christopher M., et al.
Publicado: (2023) -
Host-cell Interactions of Engineered T cell Micropharmacies
por: Bourne, Christopher M., et al.
Publicado: (2023) -
Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease
por: Saleh, Amr H., et al.
Publicado: (2023) -
Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery
por: Gardner, Thomas J., et al.
Publicado: (2020) -
Lentivirus-mediated gene therapy for Fabry disease
por: Khan, Aneal, et al.
Publicado: (2021)